Region · 8 analyses
France assesses on two scales — one sets reimbursement eligibility, the other anchors the price — and an early-access route can set the effective price before either concludes.
Two ratings decide a medicine's position in France. SMR determines whether it is reimbursed and at what statutory rate. ASMR measures added value against existing therapy and anchors the price negotiated with the pricing committee. An asset can be reimbursed and still be priced modestly, because the two questions are answered separately.
The scope of the reimbursement opinion matters as much as the rating. Where a favourable opinion is given for one line of therapy only, every patient outside it leaves the addressable population before price is discussed at all — a restriction that shapes commercial value more than the price itself.
France also runs an early-access route that admits a medicine before its European licence takes effect, with rebates accruing from the first invoice and reconciled once the definitive price lands. An asset can therefore be treating patients, and accruing a liability, months before its formal assessment concludes. A launch plan that starts at the definitive appraisal has already missed the decision that set the price.
AXLRx France reports work through that sequence: the early-access opportunity and its cost, the reimbursement scope to expect, and the negotiation the rating sets up.